Drug intelligence / Profile preview

Peptide 5A

Development stage: Preclinical
Modality: Peptides
Administration: Intraperitoneal

Overview

Peptide 5A is a CD36 antagonist investigated for its potential to ameliorate vancomycin-induced acute kidney injury (AKI). Studies in mice have shown that Peptide 5A treatment significantly mitigates the decline in glomerular filtration rate (GFR) and reduces kidney injury scores caused by vancomycin. Its protective mechanisms are hypothesized to include blocking vancomycin entry into cells, reducing inflammation, and/or preventing cell death.

Targets

CD36 (CD36 antigen)

Beyond the preview

Go deeper on Peptide 5A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Peptide 5A.

Explore the full profile